NCT06706752 A Study of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Cancer Patients Undergoing Chemotherapy
| NCT ID | NCT06706752 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sutter Health |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-01-24 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-01-24 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to assess whether Shengbai Oral Formula is a viable option for treatment of fatigue, pain, and neutropenia in patients undergoing their third cycle of chemotherapy.
Eligibility Criteria
Inclusion Criteria: 1. 18-80 years of age 2. A cancer diagnosis and scheduled to undergo at least three rounds of chemotherapy for curative or palliative intent 3. Chemotherapy is given at a minimum of every 2 weeks 4. At least 30 days past radiation therapy 5. Nonpregnant and use of method of contraception per the treating clinician standard of care 6. Life expectancy \> 3 months 7. Stable on all herbal or complementary therapeutics for the past 30 days and agree to not include new complementary therapeutics until after study completion 8. Baseline ECOG ≤ 2 9. In the opinion of the investigator, the subject will be compliant and have a high probability of completing the study including all scheduled evaluations and required tests Exclusion Criteria: 1. Abnormal ALT/AST: \> 2.5 to 3 times normal range 2. eGFR \<60 3. Platelets \< 75,000 4. Hb \<8.0 5. ANC \<1000 6. Documentation of a bone marrow transplant 7. Documentation of brain metastases, diagnosis with other cancer, except skin cancer history with basal cell carcinoma, squamous carcinoma 8. Documentation of current seizure disorder 9. Documentation of new cardiac arrhythmias and myocardial infarction 10. Any active bacterial or viral infection, pneumonia, sepsis, active gastric ulcer, gastritis, nonhealing wound, intractable nausea or vomiting, diarrhea, bleeding disorder 11. Hyperthyroidism, connective tissue disease including systemic lupus erythematous, rheumatoid arthritis 12. Documentation of a current drug abuse disorder 13. Current participation in other clinical trial
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06706752 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06706752 currently recruiting?
Yes, NCT06706752 is actively recruiting participants. Contact the research team at janet.han@sutterhealth.org for enrollment information.
Where is the NCT06706752 trial being conducted?
This trial is being conducted at Oakland, United States.
Who is sponsoring the NCT06706752 clinical trial?
NCT06706752 is sponsored by Sutter Health. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.